Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03MLA
|
||||
| Former ID |
DNC012343
|
||||
| Drug Name |
PT-302
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H12FN3S2
|
||||
| Canonical SMILES |
C1=CC(=CC=C1CCNC(=S)NC2=NC=CS2)F
|
||||
| InChI |
1S/C12H12FN3S2/c13-10-3-1-9(2-4-10)5-6-14-11(17)16-12-15-7-8-18-12/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
|
||||
| InChIKey |
WGSDLRNUZBUXDV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | HIV-1 reverse transcriptase | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00964262) A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide. U.S. National Institutes of Health. | ||||
| REF 2 | J Med Chem. 1995 Dec 8;38(25):4929-36.Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studiesof PETT analogs. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.